Leuko Labs
Leuko is an MIT spinout developing PointCheck, the world's first medical device that can monitor white blood cells non-invasively. By enabling more frequent at-home monitoring, Leuko aims to improve clinical outcomes for more than 2M cancer patients a year in the US, reduce their chemotherapy-related hospital admissions by 50 percent, and save more than $6B annually in healthcare costs.
Company Ownership:
Socially Disadvantaged
Contact Name:
Carlos Castro-Gonzalez
Contact Email:
Website:
https://leuko.com
City, State – Congressional District:
Boston,
MA
–
7
Technology:
Medical Device
Funding:
Cancer (NCI)
NIH Projects:
NIH RePorter for
Leuko Labs
Sponsored Event(s):
The MedTech Conference | 2021
,
HLTH | 2023
,
MedCity INVEST | 2025
